Atopic dermatitis is a systemic inflammatory disorder where both innate immune cells such as dendritic cells (DCs) and adaptive immune cells, such as B and T cells, contribute to cutaneous inflammation. B and T lymphocyte attenuator (BTLA), highly expressed in mature DCs, is crucial to modulate the activity of all immune cells and acts as a co-inhibitory checkpoint receptor.
Researchers from Paragon Therapeutics Inc. presented the preclinical characterization of ORKA-001 (PR-035), a novel half-life extended monoclonal antibody targeting the p19 subunit of IL-23, designed to treat chronic skin disorders such as plaque psoriasis.
Novartis AG is enlisting the help of Generate:Biomedicines Inc. and its artificial intelligence platform to generate drugs for multiple undisclosed targets. The number of targets and therapeutic areas also weren’t disclosed. Novartis will pick the targets, although the targets Generate has been working on are off limits. Generate will be responsible for creating the lead candidate, at which point Novartis will take over development.
Despite a phase IIa failure in 2018 for lupus, Biogen Inc. and UCB Inc. maintained their collaboration and now have new positive data for their anti-CD40L candidate. Top-line phase III data show dapirolizumab pegol, along with the standard of care (SOC), met the primary endpoint in demonstrating an improvement in moderate to severe systemic lupus erythematosus compared to placebo and SOC at 48 weeks.
Novartis AG is enlisting the help of Generate:Biomedicines Inc. and its artificial intelligence platform to generate drugs for multiple undisclosed targets. The number of targets and therapeutic areas also weren’t disclosed. Novartis will pick the targets, although the targets Generate has been working on are off limits. Generate will be responsible for creating the lead candidate, at which point Novartis will take over development.
Chengdian (Suzhou) Biopharmaceutical Co. Ltd. has received IND clearance from the FDA, allowing it to initiate a first-in-human phase I trial of CD-001.
Chengdian (Suzhou) Biopharmaceutical Co. Ltd. has received IND clearance from the FDA, allowing it to initiate a first-in-human phase I trial of CD-001.
Rakuten Medical Inc. has presented preclinical results with RM-0256, a PD-L1-targeted photoimmunotherapy, showing its ability to kill immunosuppressive myeloid cells to activate local and systemic antitumor immunity.
UL16 binding protein 6 (ULBP6) is a molecule belonging to the stress-induced NKG2D ligand family and its expression is up-regulated on the surface of cancerous cells, binding to the immune-activating NKG2D receptor on natural killer (NK) and T cells, thus promoting immune evasion.
A drive to overcome the limitations of traditional antibodies led Toronto-based scientists Jean-Philippe Julien and Bebhinn Treanor to work toward discovering a multivalent, multispecific platform to develop therapies that can reach difficult targets. As a result, through the support of VC firm Amplitude Ventures, Radiant Biotherapeutics emerged in 2020 armed with what has become its Multabody platform.
RSS
